A Phase I, Open-Label, Dose-Escalation Study to Investigate the Safety, Tolerability, PD and PK of EMD 525797 Using DCE-MRI as a PK Measure of Response in Colorectal and Ovarian Cancer Patients With Liver Metastases After Failure of Standard Therapy
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2015
At a glance
- Drugs Abituzumab (Primary)
- Indications Colorectal cancer; Liver metastases; Ovarian cancer
- Focus Adverse reactions
- Sponsors Merck KGaA
- 07 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Jan 2013 Planned number of patients changed from 24 to 40 as reported by ClinicalTrials.gov.
- 16 Jan 2013 Planned End Date changed from 1 Sep 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.